Nivolumab biosimilar(Amgen)

纳武利尤单抗生物类似药（安进）

Report date: 2026/03/09 20:02:04

Base Information

Drug NameNivolumab biosimilar(Amgen)

Drug Alias NameABP-206

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBosnia and HerzegovinaCanada +[31]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

ATC CodeN/A